10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Golden Prospects | Torex Gold transitions to positive cash flow as Media Luna project ramps up, positioning the company for growth amid rising gold prices and market interest |
Operational Milestones | Explore Torex's rapid progress at Media Luna, with commercial production achieved and ambitious mining rate targets set to outpace initial projections |
Market Dynamics | Delve into how Torex's lean financial structure may appeal to investors seeking exposure to gold's upward trend, with price targets ranging from $35 to $56 |
Navigating Challenges | Learn about Torex's resilience in overcoming recent setbacks, including production disruptions, while maintaining its annual guidance and focusing on safety |
Metrics to compare | TXG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTXGPeersSector | |
---|---|---|---|---|
P/E Ratio | −20.6x | −3.0x | −0.5x | |
PEG Ratio | −0.31 | −0.37 | 0.00 | |
Price/Book | 2.3x | 1.4x | 2.6x | |
Price / LTM Sales | 2.7x | 2.1x | 3.2x | |
Upside (Analyst Target) | 7.1% | 23.6% | 37.1% | |
Fair Value Upside | Unlock | 19.1% | 5.4% | Unlock |